UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement

Genetics in medicine, 2006-09, Vol.8 (9), p.539-548

2006

Link zum Volltext

Verfügbarkeit prüfen

Onset and progression of the Anderson–Fabry disease related cardiomyopathy

International journal of cardiology, 2008-11, Vol.130 (3), p.367-373

2008

Link zum Volltext

Verfügbarkeit prüfen

Proton pump inhibitors – do we know them well and are they really that safe? – part 3

Gastroenterologie a hepatologie, 2021-02, Vol.75 (1), p.72-83

Bultas, Jan

2021

Link zum Volltext

Verfügbarkeit prüfen

Are proton pump inhibitors an effective and safe drug not only in the prophylaxis of gastrointestinal bleeding in antithrombotic treatment?

Vnitřní lékar̆stvĭ, 2020-05, Vol.66 (3), p.169-179

Bultas, Jan

2020

Link zum Volltext

Verfügbarkeit prüfen

Proton pump inhibitors – do we know them well and are they really that safe? – part 2

Gastroenterologie a hepatologie, 2020-12, Vol.74 (6), p.547-551

Bultas, Jan

2020

Link zum Volltext

Verfügbarkeit prüfen

Proton pump inhibitors – do we know them well and are they really that safe? – part 1

Gastroenterologie a hepatologie, 2020-10, Vol.74 (5), p.431-441

Bultas, Jan

2020

Link zum Volltext

Verfügbarkeit prüfen

Inflammation and vascular diseases

Vnitřní lékar̆stvĭ, 2022-08, Vol.68 (5), p.309-314

2022

Link zum Volltext

Verfügbarkeit prüfen

Right Ventricular Involvement in Fabry Disease

Journal of the American Society of Echocardiography, 2008-11, Vol.21 (11), p.1265-1268

2008

Link zum Volltext

Verfügbarkeit prüfen

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

Nephrology, dialysis, transplantation, 2009-07, Vol.24 (7), p.2102-2111

2009

Link zum Volltext

Verfügbarkeit prüfen

Anticoagulant therapy in secondary prevention of coronary events

Vnitřní lékar̆stvĭ, 2014-12, Vol.60 (12), p.1023-1032

Bultas, Jan

2014

Link zum Volltext

Verfügbarkeit prüfen

Mountain sickness

Časopis lékařů českých, 2015, Vol.154 (6), p.280

Bultas, Jan

2015

Link zum Volltext

Verfügbarkeit prüfen

Anticoagulant therapy in the elderly

Vnitřní lékar̆stvĭ, 2018, Vol.64 (11), p.1011-1020

2018

Link zum Volltext

Verfügbarkeit prüfen

Novel oral anticoagulants – the advantages and drawbacks of the therapy

Gastroenterologie a hepatologie, 2015-04, Vol.69 (2), p.152-160

Bultas, Jan

2015

Link zum Volltext

Verfügbarkeit prüfen

Antiplatelet therapy—A pharmacologist's perspective

Cor et vasa (English ed.), 2013-04, Vol.55 (2), p.e86-e94

Bultas, Jan

2013

Link zum Volltext

Verfügbarkeit prüfen

Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?

Vnitřní lékar̆stvĭ, 2020-04, Vol.66 (2), p.97-103

2020

Link zum Volltext

Verfügbarkeit prüfen

Coagulopathy accompanying severe forms of coronavirus infection (COVID-19) - incidence of thrombotic complications, how to prevent and treat them

Cor et vasa (English ed.), 2020-06, Vol.62 (Suppl.1), p.22-26

2020

Link zum Volltext

Verfügbarkeit prüfen

Extended options of anticoagulant treatment in thromboembolism

Vnitřní lékar̆stvĭ, 2014-11, Vol.60 (11), p.977-984

2014

Link zum Volltext

Verfügbarkeit prüfen

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

Annals of internal medicine, 2007-01, Vol.146 (2), p.77

2007

Link zum Volltext

Verfügbarkeit prüfen

Fabry disease: guidelines for the evaluation and management of multi-organ system involvement

Genetics in medicine, 2006-09, Vol.8 (9), p.539-548

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenetics in cardiovascular diseases therapy--treatment according guidelines or according the individual requirement?

Časopis lékařů českých, 2010, Vol.149 (10), p.476-481

Bultas, Jan

2010

Link zum Volltext

Verfügbarkeit prüfen

Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition

Arteriosclerosis, thrombosis, and vascular biology, 2006-04, Vol.26 (4), p.839

2006

Link zum Volltext

Verfügbarkeit prüfen

Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?

European heart journal, 2010-11, Vol.31 (21), p.2650-2659

2010

Link zum Volltext

Verfügbarkeit prüfen

Relationship between X-inactivation and clinical involvement in fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population

Journal of molecular medicine (Berlin, Germany), 2005-08, Vol.83 (8), p.647-654

2005

Link zum Volltext

Verfügbarkeit prüfen

Early diastolic mitral annular velocity and color M-mode flow propagation velocity in the evaluation of left ventricular diastolic function in patients with Fabry disease

Heart and vessels, 2006-01, Vol.21 (1), p.13-19

2006

Link zum Volltext

Verfügbarkeit prüfen

A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population

Nephrology, dialysis, transplantation, 2007-01, Vol.22 (1), p.179-186

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement

Onset and progression of the Anderson–Fabry disease related cardiomyopathy

Proton pump inhibitors – do we know them well and are they really that safe? – part 3

Are proton pump inhibitors an effective and safe drug not only in the prophylaxis of gastrointestinal bleeding in antithrombotic treatment?

Proton pump inhibitors – do we know them well and are they really that safe? – part 2

Proton pump inhibitors – do we know them well and are they really that safe? – part 1

Inflammation and vascular diseases

Right Ventricular Involvement in Fabry Disease

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

Anticoagulant therapy in secondary prevention of coronary events

Mountain sickness

Anticoagulant therapy in the elderly

Novel oral anticoagulants – the advantages and drawbacks of the therapy

Antiplatelet therapy—A pharmacologist's perspective

Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only?

Coagulopathy accompanying severe forms of coronavirus infection (COVID-19) - incidence of thrombotic complications, how to prevent and treat them

Extended options of anticoagulant treatment in thromboembolism

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

Fabry disease: guidelines for the evaluation and management of multi-organ system involvement

Pharmacogenetics in cardiovascular diseases therapy--treatment according guidelines or according the individual requirement?

Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition

Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?

Relationship between X-inactivation and clinical involvement in fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population

Early diastolic mitral annular velocity and color M-mode flow propagation velocity in the evaluation of left ventricular diastolic function in patients with Fabry disease

A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population

Suchergebnisse filtern